Amgen (AMGN) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $6.31.
- Amgen's Debt to Equity fell 3832.7% to $6.31 in Q4 2025 from the same period last year, while for Dec 2025 it was $6.31, marking a year-over-year decrease of 3832.7%. This contributed to the annual value of $6.31 for FY2025, which is 3832.7% down from last year.
- Per Amgen's latest filing, its Debt to Equity stood at $6.31 for Q4 2025, which was down 3832.7% from $5.67 recorded in Q3 2025.
- Amgen's Debt to Equity's 5-year high stood at $40.23 during Q1 2022, with a 5-year trough of $3.5 in Q1 2021.
- In the last 5 years, Amgen's Debt to Equity had a median value of $9.16 in 2023 and averaged $10.14.
- As far as peak fluctuations go, Amgen's Debt to Equity soared by 104896.94% in 2022, and later crashed by 7137.37% in 2023.
- Over the past 5 years, Amgen's Debt to Equity (Quarter) stood at $4.97 in 2021, then soared by 113.98% to $10.64 in 2022, then decreased by 2.54% to $10.37 in 2023, then dropped by 1.37% to $10.23 in 2024, then plummeted by 38.33% to $6.31 in 2025.
- Its Debt to Equity stands at $6.31 for Q4 2025, versus $5.67 for Q3 2025 and $7.57 for Q2 2025.